
MediaBayer Launches Phase IIa Clinical Trial for Alport Syndrome Therapy
Bayer Launches Phase IIa Clinical Trial of Novel Therapy for Alport Syndrome Bayer has announced the initiation of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody…











